Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246156974> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4246156974 endingPage "7" @default.
- W4246156974 startingPage "7" @default.
- W4246156974 abstract "Abstract Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma with an especially poor prognosis and a median survival of only 3–4 years. In 1996, the European MCL Network initiated a randomized trial to improve the otherwise dismal outcome of MCL, comparing early consolidation with myeloablative radiochemotherapy (TBI 12 gray, cyclophosphamide 120 mg/kg bw) followed by autologous stem cell transplantation (ASCT) to a conventional a -interferon maintenance (6x106 IE IFNa 3x weekly) in first remission after a CHOP-like induction regimen. Until March 2004, a total of 269 previously untreated patients (up to 65 years) were randomized upfront. 189 (82%) of 230 patients with advanced stage MCL completed initial induction chemotherapy and 142 (75%) achieved either a complete (45 pts., 24%) or partial response (97 pts, 51%). 122 pts proceeded to consolidation therapy, 62 pts received ASCT consolidation and 60 patients were assigned to IFN maintenance. Patients in the ASCT study arm experienced a significantly longer progression-free survival (PFS) as compared to patients in the IFNa arm. The PFS at 2 years was 73% after ASCT as compared to only 43% in the IFNa arm (p = 0.0108). Similar results were achieved in the intent to treat analysis of all initially randomised MCL patients (p=0.0001). Accordingly, this advantage resulted in a trend towards an improved overall survival (OS) in the ASCT arm. After a follow-up of up to nearly 7 years (median follow-up of patients: 2.8 years), 3 year survival after ASCT was 83% in comparison to 77% under IFNa maintenance (p = 0.18). As expected, acute toxicity was higher in the ASCT group with an early mortality of 4.8%, whereas long-term effects were more frequently encountered under IFNa maintenance. Conclusion : In first line treatment of advanced stage MCL, dose-intensified consolidation with myeloablative radiochemotherapy followed by ASCT after CHOP-like induction results in a significant prolongation of PFS. Current study concepts evaluate the benefits of combined immuno-chemotherapy to further improve the overall survival." @default.
- W4246156974 created "2022-05-12" @default.
- W4246156974 creator A5001222821 @default.
- W4246156974 creator A5009186146 @default.
- W4246156974 creator A5011643510 @default.
- W4246156974 creator A5023251571 @default.
- W4246156974 creator A5030025370 @default.
- W4246156974 creator A5033935778 @default.
- W4246156974 creator A5036867361 @default.
- W4246156974 creator A5039142430 @default.
- W4246156974 creator A5046049357 @default.
- W4246156974 creator A5051276031 @default.
- W4246156974 creator A5062839406 @default.
- W4246156974 creator A5063241074 @default.
- W4246156974 creator A5069539777 @default.
- W4246156974 creator A5072302022 @default.
- W4246156974 creator A5080742745 @default.
- W4246156974 creator A5086462994 @default.
- W4246156974 creator A5086620890 @default.
- W4246156974 creator A5090187743 @default.
- W4246156974 creator A5090442302 @default.
- W4246156974 date "2004-11-16" @default.
- W4246156974 modified "2023-10-14" @default.
- W4246156974 title "Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle Cell Lymphoma - Long Term Follow up of a Prospective Randomized Trial of the European MCL Network." @default.
- W4246156974 doi "https://doi.org/10.1182/blood.v104.11.7.7" @default.
- W4246156974 hasPublicationYear "2004" @default.
- W4246156974 type Work @default.
- W4246156974 citedByCount "3" @default.
- W4246156974 countsByYear W42461569742018 @default.
- W4246156974 countsByYear W42461569742020 @default.
- W4246156974 crossrefType "journal-article" @default.
- W4246156974 hasAuthorship W4246156974A5001222821 @default.
- W4246156974 hasAuthorship W4246156974A5009186146 @default.
- W4246156974 hasAuthorship W4246156974A5011643510 @default.
- W4246156974 hasAuthorship W4246156974A5023251571 @default.
- W4246156974 hasAuthorship W4246156974A5030025370 @default.
- W4246156974 hasAuthorship W4246156974A5033935778 @default.
- W4246156974 hasAuthorship W4246156974A5036867361 @default.
- W4246156974 hasAuthorship W4246156974A5039142430 @default.
- W4246156974 hasAuthorship W4246156974A5046049357 @default.
- W4246156974 hasAuthorship W4246156974A5051276031 @default.
- W4246156974 hasAuthorship W4246156974A5062839406 @default.
- W4246156974 hasAuthorship W4246156974A5063241074 @default.
- W4246156974 hasAuthorship W4246156974A5069539777 @default.
- W4246156974 hasAuthorship W4246156974A5072302022 @default.
- W4246156974 hasAuthorship W4246156974A5080742745 @default.
- W4246156974 hasAuthorship W4246156974A5086462994 @default.
- W4246156974 hasAuthorship W4246156974A5086620890 @default.
- W4246156974 hasAuthorship W4246156974A5090187743 @default.
- W4246156974 hasAuthorship W4246156974A5090442302 @default.
- W4246156974 hasConcept C126322002 @default.
- W4246156974 hasConcept C141071460 @default.
- W4246156974 hasConcept C143998085 @default.
- W4246156974 hasConcept C168563851 @default.
- W4246156974 hasConcept C2776694085 @default.
- W4246156974 hasConcept C2776755627 @default.
- W4246156974 hasConcept C2777525834 @default.
- W4246156974 hasConcept C2778336483 @default.
- W4246156974 hasConcept C2778476033 @default.
- W4246156974 hasConcept C2779050716 @default.
- W4246156974 hasConcept C2779338263 @default.
- W4246156974 hasConcept C2780739268 @default.
- W4246156974 hasConcept C2781413609 @default.
- W4246156974 hasConcept C2911091166 @default.
- W4246156974 hasConcept C71924100 @default.
- W4246156974 hasConceptScore W4246156974C126322002 @default.
- W4246156974 hasConceptScore W4246156974C141071460 @default.
- W4246156974 hasConceptScore W4246156974C143998085 @default.
- W4246156974 hasConceptScore W4246156974C168563851 @default.
- W4246156974 hasConceptScore W4246156974C2776694085 @default.
- W4246156974 hasConceptScore W4246156974C2776755627 @default.
- W4246156974 hasConceptScore W4246156974C2777525834 @default.
- W4246156974 hasConceptScore W4246156974C2778336483 @default.
- W4246156974 hasConceptScore W4246156974C2778476033 @default.
- W4246156974 hasConceptScore W4246156974C2779050716 @default.
- W4246156974 hasConceptScore W4246156974C2779338263 @default.
- W4246156974 hasConceptScore W4246156974C2780739268 @default.
- W4246156974 hasConceptScore W4246156974C2781413609 @default.
- W4246156974 hasConceptScore W4246156974C2911091166 @default.
- W4246156974 hasConceptScore W4246156974C71924100 @default.
- W4246156974 hasIssue "11" @default.
- W4246156974 hasLocation W42461569741 @default.
- W4246156974 hasOpenAccess W4246156974 @default.
- W4246156974 hasPrimaryLocation W42461569741 @default.
- W4246156974 hasRelatedWork W2013342102 @default.
- W4246156974 hasRelatedWork W2014285677 @default.
- W4246156974 hasRelatedWork W2120703089 @default.
- W4246156974 hasRelatedWork W2316103550 @default.
- W4246156974 hasRelatedWork W2470400696 @default.
- W4246156974 hasRelatedWork W2522899364 @default.
- W4246156974 hasRelatedWork W2566092500 @default.
- W4246156974 hasRelatedWork W2587468415 @default.
- W4246156974 hasRelatedWork W4246156974 @default.
- W4246156974 hasRelatedWork W2241811306 @default.
- W4246156974 hasVolume "104" @default.
- W4246156974 isParatext "false" @default.
- W4246156974 isRetracted "false" @default.
- W4246156974 workType "article" @default.